This plays a role in tumor promotion in HER2+ breast cancer with high CDK12 expression associated with poor overall survival (OS) and disease-free survival [25–27]; CDK12 has also been shown to play an anticancer role in triple-negative breast cancer [21]. This evidence concerns the gene CDK12 and triple-negative breast carcinoma.